131 related articles for article (PubMed ID: 12756053)
1. Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis.
Rajwal SR; Stringer MD; Davison SM; Gerrard M; Glaser A; Tanner MS; McClean P
Pediatr Transplant; 2003 Jun; 7(3):247-51. PubMed ID: 12756053
[TBL] [Abstract][Full Text] [Related]
2. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
5. First experience with basiliximab in pediatric liver graft recipients.
Ganschow R; Broering DC; Stuerenburg I; Rogiers X; Hellwege HH; Burdelski M
Pediatr Transplant; 2001 Oct; 5(5):353-8. PubMed ID: 11560755
[TBL] [Abstract][Full Text] [Related]
6. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis.
Yuksekkaya HA; Arikan C; Tumgor G; Aksoylar S; Kilic M; Aydogdu S
Pediatr Transplant; 2011 Sep; 15(6):E105-9. PubMed ID: 21884342
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy.
Venzke A; Ganschow R; Grabhorn E; Rogiers X; Burdelski M
Pediatr Transplant; 2003 Oct; 7(5):404-7. PubMed ID: 14738304
[TBL] [Abstract][Full Text] [Related]
8. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
Arora N; McKiernan PJ; Beath SV; deVille de Goyet J; Kelly DA
Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure.
Shigeta T; Sakamoto S; Uchida H; Sasaki K; Hamano I; Kanazawa H; Fukuda A; Kawai T; Onodera M; Nakazawa A; Kasahara M
Pediatr Transplant; 2014 Dec; 18(8):860-7. PubMed ID: 25311536
[TBL] [Abstract][Full Text] [Related]
11. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
[TBL] [Abstract][Full Text] [Related]
12. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.
Asensio M; Margarit C; Chavez R; Ortega J; Charco R; Iglesias J
Transplant Proc; 2002 Aug; 34(5):1970-1. PubMed ID: 12176650
[No Abstract] [Full Text] [Related]
13. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients.
Newland DM; Royston MJ; McDonald DR; Nemeth TL; Wallace-Boughter K; Carlin K; Horslen S
Pediatr Transplant; 2019 Dec; 23(8):e13573. PubMed ID: 31512802
[TBL] [Abstract][Full Text] [Related]
14. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
[TBL] [Abstract][Full Text] [Related]
15. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab reduces acute liver allograft rejection in pediatric patients.
Strassburg A; Pfister ED; Arning A; Nashan B; Ehrich JH; Melter M
Transplant Proc; 2002 Sep; 34(6):2374-5. PubMed ID: 12270443
[No Abstract] [Full Text] [Related]
17. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
[TBL] [Abstract][Full Text] [Related]
18. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis.
Braier J; Ciocca M; Latella A; de Davila MG; Drajer M; Imventarza O
Med Pediatr Oncol; 2002 Mar; 38(3):178-82. PubMed ID: 11836717
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
